Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme

• Published in: Journal of neuro-oncology Vol. 136; no. 3; pp. 463 - 474
• Main Authors: Han, Jing, Puri, Raj K.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.02.2018; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating - therapeutic use; Biomarkers, Pharmacological - metabolism; Biomarkers, Tumor - metabolism; Brain cancer; Brain Neoplasms - drug therapy; Brain Neoplasms - genetics; Brain Neoplasms - metabolism; Brain Neoplasms - mortality; Brain tumors; Cancer vaccines; Chemotherapy; Data processing; Databases, Genetic; DNA microarrays; Drug resistance; Drug Resistance, Neoplasm - physiology; Female; Gene expression; Gene Expression Regulation, Neoplastic; Genomes; Glioblastoma; Glioblastoma - drug therapy; Glioblastoma - metabolism; Glioblastoma - mortality; Glioblastoma multiforme; Humans; Immunosuppression; Immunotherapy; Immunotoxins; Interleukin 13; Interleukin-13 Receptor alpha1 Subunit - metabolism; Interleukin-13 Receptor alpha2 Subunit - metabolism; Laboratory Investigation; Lymphocytes T; Male; Medical prognosis; Medicine; Medicine & Public Health; Middle Aged; Monocyte chemoattractant protein 1; Neurology; Oncology; Prognosis; RNA, Messenger - metabolism; Temozolomide; Temozolomide - therapeutic use; Tumors; GBM (glioblastoma multiforme); Biomarker; TCGA (the cancer genome atlas); IL-13Rα1; IL-13Rα2

Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. A variety of targeted agents are being tested in the clinic including cancer vaccines, immunotoxins, antibodies and T cell immunotherapy for GBM. We have previously reported that IL-13 receptor subunits α1 and α2 of IL-1...